Peng Li

Peng Li

Auto-generated profile, based on publicly available information

Peng Li

Institution of Microbiology, Jiangxi Academy of Science, Jiangxi, Nanchang, China; State Key Laboratory for Microbial Metabolism, Joint International Laboratory on Metabolic & Developmental Sciences and School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, 200030, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2022 in Microbiological Research
Verified
Journal Article
Closed access
PLPeng Li
Peng Li
JZJinqi Zhang
Jinqi Zhang
Zixin DengZixin Deng
Zixin Deng
FGFeng Gao
Feng Gao
HOHong-Yu Ou
Hong-Yu Ou

10 November 2021 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
LPLi Peng
Li Peng
LCLizhi Cao
Lizhi Cao
SNSujata Nerle
Sujata Nerle
RLRobert LeBlanc
Robert LeBlanc
ADAbhishek Das
Abhishek Das
JBJames Broderick
James Broderick
Background Sialoglycans, a type of glycans with a terminal sialic acid, have emerged as a critical glyco-immune checkpoint that impairs antitumor response by inhibiting innate and adaptive immunity. Upregulation of sialoglycans on tumors has been observed for decades and correlates with poor clinical outcomes across many tumor types. We previously showed that targeted desialylation of tumors using a bifunctional sialidase x antibody molecule, consisting of sialidase and a tumor-associated antigen (TAA)-targeting antibody, has led to robust single-agent efficacy in mouse tumor models. In addition to tumor cells, most immune cells present substantially more abundant sialoglycans than non-hematological healthy cells, which may also contribute to immunosuppression. Therefore, we studied the impact of immune cell desialylation and evaluated the therapeutic potential of a newly developed sialidase-Fc fusion (Bi-Sialidase), which lacks a TAA-targeting moiety and consists of engineered human neuraminidase 2 (Neu2) and human IgG1 Fc region, in preclinical mouse tumor models. Methods The first generation Neu2 variant was further optimized to improve titers and stability to constructed Bi-Sialidase. Bi-Sialidase’s desialylation potency and impact on immune responses were studied in vitro using various human immune functional assays, including T-cell activation, allogeneic mixed lymphocyte reaction, antibody-dependent cellular cytotoxicity, macrophages polarization/activation, neutrophil activation, and peripheral blood mononuclear cell (PBMC) cytokine release assays. We evaluated its antitumor efficacy in mouse tumor models. Bi-Sialidase’s safety profile was characterized by conducting rat and non-human primate (NHP) toxicology studies. Results The optimized Bi-Sialidase achieved a titer of 2.5 g/L from a 15-day fed-batch Chinese hamster ovary cell culture; in contrast, the wild-type and first-generation Neu2 had no production or a low titer (<0.1 g/L) under similar conditions, respectively. We demonstrated that Bi-Sialidase led to dose-dependent desialylation of immune cells and potentiated T-cell immunity, without impacting NK, macrophage, or neutrophil activation by desialylating immune cells. Activated and exhausted T cells upregulated surface sialoglycans and Bi-Sialidase-mediated desialylation reinvigorated exhausted-like T cells as measured by IFNg production. Bi-Sialidase treatment also enhanced DC priming and activation of naïve T cells by desialylating both T cells and DCs. Furthermore, Bi-Sialidase showed single-agent antitumor activity in multiple mouse tumor models, including MC38, CT26, A20, and B16F10. Importantly, Bi-Sialidase did not cause cytokine release in human PBMC assays and was tolerated to up to 100 mg/kg in rats and NHPs, demonstrating a wide safety margin. Conclusions Bi-Sialidase with an optimized Neu2 offers a novel immunomodulatory approach to enhancing T-cell immunity by desialylating immunosuppressive sialoglycans for cancer treatment.

1 January 2026 in BioResources
Verified
Journal Article
Closed access
PLPeng Li
Peng Li
CZCheng Zhang
Cheng Zhang
JNJunhui Nie
Junhui Nie
DXDawei Xiong
Dawei Xiong
SZShuaiwen Zhang
Shuaiwen Zhang
LYLin Yuan
Lin Yuan
Endoglucanase plays a vital role in lignocellulose degradation, yet the functional diversity of glycosyl hydrolase 12 (GH12) endoglucanases remains underexplored. In this study, TpCel12a, a novel GH12 endoglucanase from Talaromyces pinophilus Y117 was identified and characterized. It exhibited optimal activity at pH 4.0 and 40 °C with a preference for xyloglucan. Size exclusion chromatography revealed a monomeric state of TpCel12a. Despite classification into the promiscuous subfamily I, TpCel12a showed strict specificity for xyloglucan and carboxymethyl cellulose, yielding XXXG-type oligosaccharides and glucose/cellobiose, respectively. A loop 3 insertion mutant, designated as TpCel12a(+TQA), enhanced substrate affinity (5-fold lower Km) but reduced activity, suggesting a trade-off between binding and catalysis. Surprisingly, TpCel12a inhibited the hydrolytic efficiency of native T. pinophilus crude cellulase on corn cob powder, coinciding with its undetectable secretion under microcrystalline cellulose induction. This study highlights TpCel12a’s unique biochemical properties and its unexpected antagonistic role in native cellulase systems, offering insights for engineering fungal enzyme cocktails.